source
- Sofinnova Partners raises €725M crossover fund to back later-stage European biotech firmsSofinnova Partners, a leading European life‑science venture firm, announced that it has closed a second crossover fund worth 725 million euros (about $815 million). The new vehicle, called Sofinnov…
- Emerging biotech hubs like India could help lower global drug costs by scaling developmentThe article notes that every new therapy raises two core questions: can it be created and can society afford it. Historically biotech has focused on the first question. The author argues that as s…